Background According to some current guidelines, extended thromboprophylaxis after hip and knee arthroplasties is recommended. Outpatient prophylaxis with low molecular weight heparins (LMWH) is an important part of this prophylaxis, although the rates of adherence to these regimens is not known. Questions/purposes We determined (1) the degree of nonadherence (NA) of patients with LMWH outpatient prophylaxis, and (2) whether specific independent factors explain NA. Methods NA was determined by syringe count and by indirect and direct questions to patients. We defined six different NA indicators. To identify factors explaining LMWH NA, we used three different logistic regression models. Results NA rates ranged between 13% and 21% depending on the indicator used for measurement. Patients who were nonadherent missed between 38% and 53% of their outpatient LMWH injections. If patients attended an outpatient rehabilitation program, the probability for their NA increased substantially. Moreover, the NA probability increased with each additional day between acute hospitalization and start of rehabilitation (linking days). NA was lower for patients who feared thrombosis or who believed antithrombotic drugs to be the most important measure in thromboprophylaxis.
Introduction
The importance of medication-based or other forms of thromboprophylaxis after hip and knee arthroplasties (ie, major orthopaedic surgery) is well documented [4, 9, 14, 15, 27, 50, 52] . Therefore, thromboprophylaxis has been included in international guidelines [2, 13, 21, 22] . Current American College of Chest Physicians (ACCP) guidelines recommend medication-based thromboprophylaxis for at least 10 days (Evidence Grade 1A) postoperatively, but preferably for as much as 35 days (Evidence Grade 1A for THAs, Evidence Grade 2B for TKAs [2, 13, 21, 22] ).
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In Europe, orthopaedic thromboprophylaxis has been dominated by the use of LMWHs [39] . In Germany, there is a clear trend toward shorter hospitalization of patients after major orthopaedic surgery, leading to greater importance of outpatient thromboprophylaxis [51] . However, the question arises whether the level of LMWH prophylaxis adherence in an outpatient setting is sufficient to ensure effective treatment. This is particularly topical because the recent introduction of oral direct thrombin inhibitors provides easier administration and potentially could provide better adherence [18, 19] . Oral direct thrombin inhibitors are reportedly as effective as LMWHs [17, 19, 23, 37] but more cost-effective from a hospital's perspective [56] . Furthermore, analysis of patients' preferences showed they have a clear preference for oral thromboprophylaxis, especially in an outpatient setting [55] .
We identified seven studies reporting NA to LMWH thromboprophylaxis after surgery, with NA rates ranging from 5% to 45% [10, 33, 35, 38, 41, 49, 54] . However, almost none of the studies measured the patients' NA in real-world conditions: the studies were conducted in single centers or the NA measurement conditions failed to reflect real-world circumstances. Further, NA measurement was influenced by several factors such as preceding training and education programs for patients [10, 35, 38, 41, 54] , use of special reporting cards for documentation of injections administered by the patients to themselves [10, 38] , high frequency of visits by physicians [38] , or concurrent testing of special devices for LMWH injections [33] .
Following the WHO definition, medication NA in general can be defined as the extent to which a person's drugtaking behavior corresponds with instructions from a healthcare provider [30, 45] . There is no clinically based NA threshold in thromboprophylaxis, owing to a dearth of evidence informing the number of LMWH missed injections that would result in a substantially increased risk of thrombosis or pulmonary embolism (PE). Therefore, in accordance with most of the cited publications dealing with LMWH NA, we defined a patient who was LMWH-specific nonadherent as one who missed an LMWH injection on at least one day even though the treating clinic had recommended such an injection. To deal with the uncertainty concerning the NA threshold, (1) we defined the possible threshold in terms of alternatives (2 or 3 days), and (2) we also provide the number of noninjection days for each level of NA.
Only if the exact causes of NA are addressed is it possible to formulate an effective adherence program [28, 29, 42] . Existing general medication adherence research shows a patient's adherence is influenced by many factors ranging from sociodemographic, socioeconomic, illness-related, patient-related, and medication-specific to health systemrelated factors [12, 24, 36, 45, 58] . One of the tasks is to identify which of these possible causes are important in LMWH outpatient treatment.
We therefore (1) determined whether there was realworld NA of patients in LMWH outpatient prophylaxis, and (2) generated hypotheses concerning which specific independent factors can explain this NA.
Patients and Methods
We report results of a telephone survey conducted between June 2008 and February 2009. We interviewed 1495 patients who had major orthopaedic surgery at 22 different clinics in Germany (Appendix 1). NA was measured using six different indicators based on the previously mentioned different NA thresholds. NA reasons were identified based on multivariate regression models. As parts of our study were designed to be hypothesis generating, a sample size power analysis was not conducted. The study protocol was reviewed and approved by the University of Hannover ethical board.
To enroll study patients, we invited 106 acute and rehabilitation hospitals and 77 outpatient rehabilitation institutions (all referred to as clinics in the following text) to participate in the study. Each of these institutions is known to treat at least 100 patients having hip or knee replacement surgery per year. Ultimately, 10 acute hospitals, four inpatient rehabilitation hospitals, and eight outpatient rehabilitation institutions identified patients who had hip or knee arthroplasty for the interviews; all other institutions refused participation because of the workload associated with patient enrollment. Our potential sample included all patients in these clinics who were scheduled for or already had hip or knee arthroplasty, and who were able to answer questions in a telephone interview. The initial sample size (1771 persons) ( Fig. 1 ) was reduced because 16% (276 patients) refused informed consent or could not be interviewed because of poor status of health. Consequently, interviews were performed with 1495 patients (Table 1) . Patients refusing interviews were older than the average for the total sample by 5 years; women refused interviews with a greater (p = 0.016) frequency than men (10.6% versus 5.0%).
Concerning the conduct of the study, neither ward personnel in the clinics nor the patients were informed about the true objectives of the study. Patients were interviewed by five trained interviewers using a pretested electronic questionnaire (Appendices 2-4). Interviewers had to learn the content of the questionnaire; were educated in the normal treatment of a patient who had major orthopaedic surgery after release from the acute hospital; and were given detailed information regarding thrombosis medication alternatives available on the market. In addition, each of the interviewers had to conduct two to five trial interviews under supervision. The interviewers did not have medical degrees, because the level of medical knowledge necessary to conduct the interviews was not advanced. During each interview, data were documented online by the interviewers and stored in a Microsoft 1 Access 1 database (Microsoft Corp, Redmond, WA). To clarify possible incidences of data inconsistency, each interview also was saved electronically as an audio file. The average interview was conducted on the 41st day (SD, 6.8 days) after surgery; it lasted approximately 10 to 15 minutes.
Clinical parameters were not documented, except for thrombosis or embolus-related or unspecified complications the patients faced after surgery. Complications were not documented for patients who refused the interview or were unable to participate in the study because of clinical complications. Consequently, it is likely the number of general and thrombosis or embolus-related complications is underestimated.
The specific thromboprophylaxis pathway was identified for each patient. This was done to allow detailed comparison of the theoretically achievable and actual adherence profiles. Pathway stages were identified by reference to the normal course of clinical treatment. Consequently, each patient's postoperative pathway contained as many as six stages during which prophylaxis could be administered: (1) acute hospitalization, (2) inpatient stationary rehabilitation, (3) outpatient rehabilitation, and/or (4) at home between acute hospitalization and inpatient or outpatient rehabilitation (linking days), (5) after rehabilitation if prophylaxis is still needed, and (6) on an outpatient basis without any rehabilitation. The average desired duration of postsurgery thromboprophylaxis for each clinic and therefore per patient group was defined based on the recommendation of the clinic that enlisted the patient in the study. These recommendations were provided by the clinics; all clinics confirmed that they recommended daily injections. The duration of prophylaxis recommended by the patient's clinic was taken to be the minimum possible actual number of days of recommended treatment. This figure was used as a comparison with patients' responses, unless a patient reported that in his special case more injection days had been recommended. For NA analysis, the 1315 patients who underwent outpatient thromboprophylaxis for at least 1 day were included ( Fig. 1 ; Table 1 ). Generally, a patient's NA can be measured using direct and indirect approaches [1, 25, 30, 32, 45, 46, 48, 58] . Possible direct methods are face-toface observation of patients, and/or measurement of clinical parameters related to drug use. Indirect methods can include various instruments ranging from medication event measurement systems, patients' diaries, methods based on counting prescriptions, pills or syringes, or prescription refills, and indirect and direct questioning of patients regarding NA [11] .
A face-to-face observation of 1315 patients is neither advisable (as it would likely lead to more adherence and create observational bias) nor can it be implemented in any real-world study design. Measurement of clinical parameters (blood testing for anticoagulation effects) was excluded for conceptual (observation bias), clinical, and practical reasons. The use of a medication event measurement system (MEMS), patients' diaries, and prescription and refill counts were seen as impracticable. Because of the number of participating clinics and patients, and because of the diversity of patient pathways, the use of electronically prepared syringes (MEMS) was virtually impossible. The use of diaries runs the risk of behavioral change. Regarding prescription counts, patients in Germany have free choice of the pharmacy to which to take their prescriptions; prescription count from that side is extraordinarily complex. Administrative data regarding number of prescription refills issued could not be obtained from healthcare insurance providers either.
We used all three remaining defined methods for NA measurement; syringe counting, indirect, and direct questioning. On this basis, six NA indicators were defined ( Table 2 ). This multiple indicator concept is in line with current recommendations given for adherence measurement [40, 45] . However, there is a certain hierarchy of NA categories in terms of their predictive capacity ( Table 2 ).
In the current literature regarding NA, five main variable groups are discussed as factors potentially influencing a patient's adherence [36, 45, 58] . Variables representing each of these categories were included in the multivariate analysis in this study. Age and gender, general living circumstances, and highest education grade attained were used as sociodemographic characteristics. Illness-related factors used were the type of surgery and the existence and number of chronic diseases. The patients' views regarding thrombosis and thromboprophylaxis were used as variables representing patient-related influences. The medicationspecific factors used for multivariate design were the number of different drugs (subdivided into those in syringes and others) taken by the patient and the duration of the different steps in the patients' pathways. Finally, as healthcare or system-related factors, the specific clinic, type of clinic enlisting the patient, and pathway-specific details were used as explanatory variables.
To measure NA (primary study objective), we computed descriptive statistics and reported the results in percentages. The number of noninjection days is reported as a All indicators are based on answers given by the patients during the interviews; to clarify indicator definition, an example of a typical patient is given; many patients fell into more than one NA category. Example patient: clinic recommended postsurgery thromboprophylaxis for 35 days; patient spent 10 days in acute hospital, 3 linking days at home before stationary inpatient rehabilitation, 20 days at rehabilitation clinic, 2 remaining prophylaxis days at home after rehabilitation; interview date: 37 days after surgery. NA = nonadherence; LMWH = low-molecularweight heparin.
series of arithmetic means and the variation in a group of patients as standard deviations. The secondary study outcome was determined using the aforementioned six NA indicators (Table 2 ). In total, three multivariate logistic regression models with different dependent variables were used; the existence of a strongly probable NA measured by the categories NA I and/or NA II (Model 1), the existence of a probable NA by Model 1 plus NA III (Model 2), the existence of a possible NA by Model 2 plus NA IVa, NA IVb, and NA V (Model 3). Patients were included in Model 3 only if all of the three remaining NA categories (NA IVa, IVb and V) applied. Multivariate logistic regression analysis was performed using backward stepwise elimination to parsimoniously determine the factors most associated with NA, as follows. The initial models included all patient-reported factors ( Table 1 ). In the backward stepwise iterations, regression terms at a significance level of p [ 0.10 were successively eliminated. To reduce multicolinearity, the duration of linking was centered, by subtracting the mean from each value. The logistic regression analyses were adjusted for age, gender, living circumstances, education, and clinic.
All statistical analyses were performed using STATA1 10 statistical software (StataCorp LP, College Station, TX). All tests were two-tailed.
Results
Our data show that there is LMWH NA in outpatient thromboprophylaxis. The LMWH NA rates found in our sample range from 12.9% to 20.8% depending on the NA indicator used (Fig. 2; Table 3 ). Approximately 12.9% of patients reported that they decided not to inject themselves or had forgotten at least one injection (NA I or NA II). If patients were nonadherent in these categories, they missed 6.4 injection days (SD, 7.77 days) on average (43.1% of all outpatient prophylaxis days). The NA rates based on the other indicators show there was probably more NA that patients did not acknowledge directly in the interviews. For approximately 19.8% of patients, NA could be evaluated as probable, either because of NA I/NA II or because of a surplus of syringes (NA III). On average, these patients missed 5.9 injection days (SD, 6.63 days), ie, 38.5% of all All percentages are related to the number of patients in subsample 2 (1315 patients); the table shows how many injections an average patients in each NA category missed because of NA; because NA V does not apply to specific thromboprophylaxis days, this information is not given for NA; One patient can belong to more than one NA category; *mean days without LMWH injection. NA = nonadherence; LMWH = low-molecular-weight heparin. AHS = Acute hospital stay; LINK = linking days between acute hospital stay and rehabilitation; INPR = inpatient rehabilitation in a rehabilitation clinic; OPR = outpatient rehabilitation in a rehabilitation center; NR = no rehabilitation; PRTP = postrehabilitation thromboprophylaxis; NORE = no rehabilitation. outpatient prophylaxis days. Almost 21% (20.8%) of patients showed at least a possible NA (either previous NA indicators and/or all remaining NA indicators apply) with an average of 6.0 missed injection days (SD, 6.54 days), which corresponds to 39.6% of all outpatient prophylaxis days. If the NA threshold as a minimum number of noninjection days is increased to 2 or 3 days, NA rates naturally decrease. However, the number of missed injection days for these patients increases (Fig. 3) .
The strongest predictor of NA in all three models was the type of rehabilitation (Table 4 ). Compared with inpatient rehabilitation, patients in outpatient rehabilitation treatment in Model 1 were approximately 5 times more likely to have poor adherence (Model 2: 8 times more likely; Model 3: 7 times more likely). Differences also existed with the centered duration of linking in reported logistic regression models. Therefore, if the duration of linking increased by 1 day above the mean (from 4.24 to * A backward elimination method was used retaining all variables considered to be potentially important; variables with p \ 0.1 remained in the final models whereas variables with p [ 0.1 were removed in the stepwise backward process; odds ratio (OR) and 95% confidence interval (CI) derived from the three logistic models adjusting for age, gender, living circumstances, education, and clinic; à reference group; § patients were asked how much they believe drugs protect from thrombosis. Volume 468, Number 9, September 2010 Nonadherence in Outpatient LMWH Thromboprophylaxis 2445 5.24 days), the probability of NA would be 1.05 times (95% CI, 1.02-1.08) greater than for patients with an average number of linking days. Patients reporting fear of thrombosis or who believed in the ability of drugs to prevent thrombosis were less likely to be nonadherent. However, these factors were significant only in Model 1 (strongly probable NA).
Discussion
The existence of guidelines for medication-based thromboprophylaxis is no guarantee of outpatient LMWH adherence. This study, involving 1495 interviewed patients and 22 clinics, is the largest empirical investigation so far to deal with LMWH outpatient NA. Our study was conducted to investigate the extent of existence of NA (primary study objective) and to generate hypotheses concerning which specific independent factors can explain this NA (secondary study objective). We were able to confirm the existence of NA and to generate hypotheses that appear to be a promising basis for identifying the responsible factors.
We acknowledge limitations to the study. First, we analyzed only an injectable medication-based thrombosis prophylaxis with LMWH after hip and knee arthroplasties. It is possible oral thromboprophylaxis medications would result in lower NA. However, in Europe LMWH prophylaxis is still the dominant form of prophylaxis [39] . Second, we used only NA indicators that could be identified with the help of patients. For this reason we are open to the risk of response bias [8, 34, 59] . However, previous research suggests an assessment of patients' adherence based on indirect or direct questioning on this topic is a good predictor of adherence [31, 43] . This technique regularly overestimates adherence by a factor of 2 [26, 29, 36, 44] . This means that although our results show that at least 12.9% of patients to be nonadherent (Model 1), the real percentage could be 20% to 30%. This matches our Model 3 where 20.8% of patients showed NA. Third, there is no clinically based NA threshold or NA model that should be used. That is why, in accordance with most of the previous publications dealing with LMWH NA, we defined a patient who was LMWH-specific nonadherent as one who missed an LMWH injection on at least one day even though the treating clinic had recommended such an injection. Although it is not possible to justify our choice of three models on the basis of clinical evidence, they have their purpose, which is to provide multiple indicators. Fourth, owing to cultural or other reasons, our analysis may be specific to Germany. Nevertheless, we suspect the results of the NA research are robust in international comparisons, for the following reason. It can be assumed drug-related outpatient prophylaxis in other countries is at least as important as it is in Germany, because most other countries do not have a comprehensive network of inpatient rehabilitation clinics. However, we have no exact knowledge concerning linking days in other countries. Fifth, there is a possibility the participating clinics did not reflect a representative sample of hip and knee arthroplasty clinics in Germany. However, the large number of clinics that participated and the large number of patients studied leads us to believe that our sample was representative. Sixth, the nonresponse rate of approximately 15.6% suggests a possible selection bias. Although there were differences in age and gender between responders and nonresponders, these variables did not influence the NA probability of a patient. Seventh, the basis for measuring patients' NA were the recommendations made by clinics. However it is possible that in some cases the general practitioners responsible for LMWH prescriptions in the outpatient setting might have given different recommendations, eg, because of drug budget constraints. In Germany, this probably is not often the case for linking days but could have been the case during outpatient rehabilitation, days without any rehabilitation, or prophylaxis days after rehabilitation. Consequently, there is some probability that we did not measure patients' NA but less prophylaxis days caused by general practitioners modifying the clinic recommendations [20] .
We found a relatively high rate of NA. This finding is in line with published studies regarding LMWH NA l [10, 33, 35, 38, 41, 49, 54] , bearing in mind our possible overestimation of adherence [29] . If patients are nonadherent, they miss approximately 40% to 50% of their entire outpatient thromboprophylaxis. Empirical research shows, after major orthopaedic surgery, clinically relevant deep venous thrombosis and PE occur at a median of 20 and 21 days after TKA and 12 and 34 days after THA [3, 53] . Our data show the linking period to be a critical phase. For an average patient in our survey, the linking period started 11.37 days (SD, 2.9 days) after surgery. For the first quartile, this period started 8.1 days after the surgery. Whether this means that NA necessarily occurs during a clinically critical phase was not further investigated by us.
Although our study suggests some initial indications concerning the factors that could explain patients' LMWH NA, it is, in this respect, a hypothesis-generating study. We believe these factors can contribute to the general discussion regarding NA causes although the findings in NA research are controversial [16, 45] . A more detailed understanding of explanatory factors is essential for development of sophisticated patient adherence programs. In particular, factors such as the detailed recommendations given by general practitioners [20] , the patient-doctor relationship [38] , the patients' education regarding thrombosis risk [41] , and psychological factors describing patients' behavior and thinking [5, 47] require more detailed investigation [12, 57] . Furthermore, because patients have a preference for oral prophylaxis [55] and because earlier studies report some adherence advantages associated with medication regimens that are perceived to be easy to follow [29] , in contrast to the more complex regimens commonly associated with some drugs [6, 7, 36, 48] , it could be assumed patients' adherence to oral thromboprophylaxis regimens is greater than is the case with LMWH prophylaxis. Whether this is the case remains a matter for future research. 
